Investigation of Synthetic Compounds in Drug Discovery by i-Series and LCMS-2020

Operational efficiency is an important issue to researchers involved in the organic synthesis stage of drug discovery typically conducted at pharmaceutical companies and universities.
Specifically, large numbers of drug candidates are synthesized daily in the drug discovery chemistry operations conducted throughout the pharmaceutical industry, and the synthesis and purity confirmation of these substances are primarily conducted by LC/MS. Typically, the LC/MS is treated as a shared instrument in an open-access environment, so rather than optimizing the analytical conditions for the various individual compounds, each type of compound is analyzed using a fixed set of analytical conditions. Further, the analyst conducting an analysis is often unaware of the type of compound that was analyzed by the previous analyst who used that instrument.
Reliable analysis in such an environment fundamentally requires an LC system that ensures low carryover performance. The i-Series integrated Ultra High Performance Liquid Chromatograph effectively suppresses carryover using specially treated liquid-contact surfaces, such as the needle seal and sampling needle, thereby providing excellent quantitative performance with high accuracy in a wide variety of analyses. Furthermore, the i-Series can be connected with the high-scan-speed LCMS-2020. The built-in UV / VIS detector or PDA detector along with connection to an LCMS permit very detailed qualitative and quantitative analysis.
Here, we introduce an example of analysis of eight pharmaceutical substances in a workflow that is typically used for pharmaceutical synthesis confirmation analysis.

Direct Access for Each Sample Rack

read more